SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-019517
Filing Date
2024-05-15
Accepted
2024-05-15 08:30:41
Documents
55
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 808469
2 ex31-1.htm EX-31.1 12545
3 ex31-2.htm EX-31.2 12552
4 ex32-1.htm EX-32.1 10372
  Complete submission text file 0001493152-24-019517.txt   4271368

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20240331.xsd EX-101.SCH 34427
6 XBRL CALCULATION FILE zvsa-20240331_cal.xml EX-101.CAL 37682
7 XBRL DEFINITION FILE zvsa-20240331_def.xml EX-101.DEF 132552
8 XBRL LABEL FILE zvsa-20240331_lab.xml EX-101.LAB 264856
9 XBRL PRESENTATION FILE zvsa-20240331_pre.xml EX-101.PRE 210765
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 724948
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 24947340
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)